On July 16th, Chison Medical Technologies Co.,Ltd. (ASX: 688358) responded to investor inquiries via an interactive platform, announcing that its independently developed "Breast AI Ultrasound Robot" has obtained a medical device test report ahead of competitors.

This integrated solution features a touchscreen, an electric examination bed, a six-degree-of-freedom robotic arm, and automated ultrasound image transmission with AI-assisted image reading, enabling large-scale scanning and data tracking management. It establishes a comprehensive closed-loop management model covering "screening, referral, and treatment."

Regarding core medical robotics technologies, the company holds an industry-leading position in areas such as visual depth point cloud data segmentation algorithms, force control algorithms, and ultrasound image servo control algorithms. These technologies are deeply integrated into its "AI + Robotic Scanning" solution, offering an innovative pathway for mass screening of malignant tumors.

The company maintains a research and development-driven core strategy, focusing on a synergistic tripartite system comprising "AI Technology Ecosystem (Brain) – High-Definition Probes (Eyes) – Ultrasound Robot (Hands)." It continues to advance the strategic reserve and iterative development of extended ultrasound innovation projects.